dm+d

Unassigned

New Medicines

Platinum-sensitive ovarian cancer - combination therapy

Information

New molecular entity
Eisai
Eisai

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
May 20Development discontinued [18].

Category

Anti-GP3 humanised monoclonal antibody
The UK incidence of OC is 21 per 100,000 people. 75% have advanced disease and up to 80% respond to first-line platinum chemotherapy; of these 55-75% relapse within 2 years.
Platinum-sensitive ovarian cancer - combination therapy
Intravenous

Trial or other data

Mar 16Results of PIII RCT (n=1100) to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse showed progression free survival of 9.0, 9.5 and 9.7 months for the placebo, farletuzumab 1.25mg/kg, and farletuzumab 2.5mg/kg groups, respectively. Neither farletuzumab group was statistically different from the placebo group [13].

Evidence based evaluations